3 results
Approved WMORecruiting
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.
Approved WMOWill not start
Protocol section 2.1:* Demonstration of the long term safety of BI655130 in patients with moderate to severe active colitis Ulcerosa who have already been treated in previous studies.* Demonstration of the long term efficacy of BI655130 in patients…
Approved WMOWill not start
To assess efficacy of INCMGA00012 in terms of the ORR in participants with locally advanced or metastatic SCAC who have progressed after platinum-based chemotherapy.